Table 2 Number and type of trials broken into groups according to cancer type.
From: Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review
Trial Type | Â | Â | Cancer Type | Â | Â | Â |
|---|---|---|---|---|---|---|
| Â | Colorectal | NSCLCa | Head-Neck | HB-Panc | Breast-Ov-Skin | TOTAL |
Phase I/II | 20 | 9* | 10* | 5 | 3 | 47 |
Phase III | 2 | 1 | 1 | 0 | 0 | 4 |
Case Series/Review | 1 | 0 | 1 | 0 | 1 | 3 |
TOTAL | 23 | 10 | 12 | 5 | 4 | 53 |
First-Line | 5 | 2 | 0 | 0 | 2 | 9 |
Refractory Disease | 18 | 8* | 12* | 5 | 2 | 44 |